peptide hormone raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-08-08 and is reviewed periodically as new material appears.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
== Derived products == A common method of producing laudanum involves dissolving the PSC or latex-derived opium in alcohol and either allowing the solution to sit for up to a week, being periodically agitated; using fresh alcohol to do multiple washes; or refluxing. The original patents for laudanum in various countries refer to soaking poppy straw with varying levels of pulverisation in plain water for a week then evaporating the water to obtain the gummy or powdery brown concentrate.
Pegulicianine, sold under the brand name Lumisight, is an optical imaging agent. It is given via intravenous injection. Pegulicianine was approved for medical use in the United States in April 2024. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.
== Adverse effects == Most common side-effects are gastrointestinal, including diarrhea, nausea, abdominal pain and vomiting. Headache and disturbances in taste also occur. Less common side-effects include palpitations, blurred vision, and rashes. Prolonged QTc intervals may also be caused by telithromycin. Rare but severe side-effects were initially reported in March 2006, involving damage to the liver. Three different incidents were reported: one case of temporary drug-induced hepatitis, one ending in a liver transplant, and one ending in death. In the United States, the FDA's Office of Epidemiology and Surveillance identified 12 cases of acute liver failure, resulting in four deaths, and an additional 23 cases of acute, serious liver injury, among 5.2 million patients taking telithromycin through April 2006. In 2010, a published report described the likely mechanism of action underlying not only the cases of liver failure but also cases of visual disturbances and exacerbations of myasthenia gravis. The study showed that a pyridine moiety that is part of the telithromycin molecule acts as an antagonist on cholinergic receptors located in the neuromuscular junction, the ciliary ganglion of the eye and the vagus nerve innervating the liver. Other macrolides, such as azithromycin and clarithromycin and the fluoroketolide, solithromycin, do not contain the pyridine moiety and do not antagonize these cholinergic receptors significantly.
In 2012 and 2014, the Aspen Institute named Santa Fe College one of the ten best community colleges in the U.S. In 2015, the college received the Aspen Prize for Community College Excellence, recognizing it as the top community college in the country. In 2015, the Lawrence W. Tyree Library received the Excellence in Academic Libraries Award from the Association of College & Research Libraries.
== Clinical studies == PF-04455242 reached phase 1 clinical trials for bipolar depression prior to the discontinuation of its development in 2010. Its development was discontinued upon unfavorable toxicological findings in animals that had been exposed to the drug for 3 months. Along with JDTic, which was also discontinued due to toxicity findings early in clinical trials, PF-04455242 was one of the first KOR antagonists to be developed for potential treatment of psychiatric disorders. It was in phase 1 trials by 2009 and was first described in the scientific literature by 2010.
Sources: en.wikipedia.org
The same month, Lineage entered the Spanish marketplace, acquiring cold storage firm Frigorificos de Navarra of Gijón, Spain from Frioastur and, in June 2021, entered the European freight industry with its acquisition of Rotterdam-based UTI Forwarding, and also acquired Kloosterboer Group in Europe, and the cold storage division of Claus Sorensen Group in Denmark. In November 2021, Lineage expanded into the Italian cold storage market with the acquisition of Kantaro SRL. In January 2022, Lineage continued its expansion by acquiring Auscold Logistics in South Australia. In the same month, Lineage also acquired Van Tuyl Logistics, as well as individual locations from H&S Coldstores in Beneden-Leeuwen and Frigocare Rotterdam BV in Rotterdam. In March, Lineage further expanded its network by acquiring MTC Logistics, adding nearly 38 million cubic feet of capacity and more than 113,000 pallet positions in the United States and its presence at key ports along the U.S. East and Gulf Coasts. In April, Lineage acquired VersaCold Logistics to expand its presence in Canada. Later in May, the company acquired Mandai Link Logistics to expand into Singapore. In August, Lineage acquired Cold Storage Nelson in New Zealand. This increased its presence in the Asia-Pacific area. In August 2023, Lineage expanded its European network by acquiring Grupo Fuentes, a Spanish transport and cold store operator. In addition, Lineage strengthened its presence in northern Vietnam through a joint venture with SK Logistics.
Due to the reduced water content of the freeze-dried foods that inhibit the growth of microorganisms and prevent enzymatic chemical reactions, these foods are considered shelf-stable and can be kept safe from spoilage for years by preventing the reabsorption of moisture. Freeze-dried foods can be stored at room temperature without the need for refrigeration. Although uncommon compared to most applications, sometimes a seasoning solution is sprayed directly onto ramen noodles to enhance their flavor, prior to being packaged. Powder seasoning packets may also contain anticaking agents and flow agents to prevent the product from clumping into a solid mass.
The former maintains its own border control policies, thus requiring physical border security at its border with the Schengen Area, as well as implementing border controls for travellers travelling directly between Gibraltar and the British mainland. The latter maintains a relatively open border with Southern Cyprus, though not with Northern Cyprus. Consequently, it is a de facto member of the Schengen Area, and travel to or from the British mainland is subject to border controls. On 31 December 2020, Spain and the United Kingdom reached an agreement in principle under which Gibraltar would join the Schengen Area, clearing the way for the European Union and the UK to start formal negotiations on the matter. In the aftermath of Brexit, border controls for goods flowing between Great Britain and Northern Ireland were introduced in accordance with the Protocol on Ireland/Northern Ireland agreed to as part of the UK's withdrawal agreement with the EU. Due to the thirty-year internecine conflict in Northern Ireland, the UK-Ireland border has had a special status since that conflict was ended by the Belfast Agreement/Good Friday Agreement of 1998. As part of the Northern Ireland Peace Process, the border has been largely invisible, without any physical barrier or custom checks on its many crossing points; this arrangement was made possible by both countries' common membership of both the EU's Single Market and Customs Union and of their Common Travel Area.
=== Peptides === Cell Surface Peptides provide one way to introduce drug delivery into a target cell. This method is accomplished by the peptide binding to a target cells surface receptors, in a way that bypasses immune defenses that would otherwise compromise a slower delivery, without causing harm to the host. In particular, peptides, such as intercellular adhesion molecule-1, have shown a great deal of binding ability in a target cell. This method has shown a degree of efficacy in treating both autoimmune diseases as well as forms of cancer as a result of this binding affinity. Peptide mediated delivery is also of promise due to the low cost of creating the peptides as well as the simplicity of their structure.
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.